Jeremie Calais
@CalaisJeremie
Nuclear medicine and theranostics at UCLA
@UCLA @UCLAJCCC @UCLATheranostic
@UCLAnewsroom @UCLAHealth
#PETCT #nuclearmedicine #theranostics
ID:1317210197765484546
16-10-2020 21:06:18
570 Tweets
1,3K Followers
188 Following
Imaging response to PSMA radiopharmaceutical therapy. At the 2024 #PSMAConference Jeremie Calais highlights the advanced diagnostic capabilities of PSMA PET/SPECT in monitoring responses to PSMA-targeted radiopharmaceutical therapy > bit.ly/3uOg7cm PSMA conference - UCSF/UCLA/PCF/Urotoday
Is Terbium-161 (¹⁶¹Tb) Really Happening ??
jnm.snmjournals.org/content/jnumed… JNM
#GraceKong James Buteau ProsTIC
ENZA-P in The Lancet Oncology
Lu-177 PSMA-617 + enzalutamide vs. enza alone:
● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects
Incredible work from Louise Emmett Ian Davis & ANZUP team…
SPECT images obtained +24h after administration of Lu177 therapy can provide valuable information and can impact patient management. #theranostics
JNM Thomas Hope SurekhaYadav MD
jnm.snmjournals.org/content/65/3/4…
#PSMA SUVmax on localised #Prostate Ca is not everything… we should also consider the PRIMARY score!
Intraprostatic analysis should take into account SUV parameters along with anatomical location of lesion.
🗺️💡 Louise Emmett James Buteau Michael Hofman Daniel Moon #ProsTIC24
The potential contribution of radiopharmaceutical therapies in managing oligometastatic disease. ow.ly/J1IG50QGt5F
#ProstateCancer #NuclearMedicine #RPTherapy Amar Kishan UCLA Jonsson Comprehensive Cancer Center Jeremie Calais
#USProstateCancerConference OncLive.com at NYC👉 Esteemed group of investigators discussing challenging areas in treatment of #prostatecancer : Excellent talk by Jeremie Calais on PSMA PET impact in BCR setting. Alan H Bryce Phillip Koo, MD
'Integration of radioligand therapy (RLT) with metastasis-directed therapy (MDT) might reduce progression, including polymetastatic progression, in the setting of oligorecurrent disease.'
State-of-the-Art review by Amar Kishan Shankar Siva Jeremie Calais on role of…
Imaging response to PSMA radiopharmaceutical therapy. At the 2024 #PSMAConference Jeremie Calais highlights the advanced diagnostic capabilities of PSMA PET/SPECT in monitoring responses to PSMA-targeted radiopharmaceutical therapy > bit.ly/3uOg7cm PSMA conference - UCSF/UCLA/PCF/Urotoday
GRPR-targeting PET/MRI localizes more disease than MRI alone for patients w/ recurrent #prostatecancer
🚨The Lancet Oncology
Link: tinyurl.com/256yh27f
Prostate Cancer Foundation UroToday.com Amer. Urol. Assn. Stanford Urology
New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !!
jnm.snmjournals.org/content/early/…
Debiopharm Ben Tran
JNM Peter Mac Research
In the #PSMA #PETimaging arm of the randomized PSMA-SRT trial UCLA and UC San Francisco, M1 disease was detected in ~10% and there was 18% more treatment escalation than in the control arm. Will this lead to improved PSA outcomes? Analysis is planned for 2025.
sciencedirect.com/science/articl…
Prognostic value of end-of-treatment PSMA PET/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis. #BeyondTheAbstract with Vishnu Murthy David Geffen School of Medicine at UCLA > bit.ly/3U5D19F JNM Jeremie Calais Johannes Czernin Andrei Gafita
Great work out in European Urology led by Wesley Armstrong on our . SRT randomized trial of PSMA vs SOC imaging before SRT, led by Jeremie Calais and Nick Nickols
The emergent role of theranostics in #RenalCellCarcinoma . Presentation by Brian Shuch, MD UCLA. #GU24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3SB5DWR ASCO
Low- and high-volume disease in #mHSPC , from #CHAARTED to PSMA-PET: An international multicenter retrospective study. Presentation by LenaUnterrainer UCLA. #GU24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3Ufz9Th ASCO
